TRIAL_ID,LSO_CHANGES,DBL_CHANGES,LSO,LSO_INTERIM_2,LSO_INTERIM_3,LSO_INTERIM_4,DBL,DBL_INTERIM_2,DBL_INTERIM_3,DBL_INTERIM_4,THERAPEUTIC_AREA,STUDY_PHASE,STUDY_STATUS,PLANNED_ENROLLMENT,CRO,PA_PS_TIME,PA_FPI_TIME,FPI_LPI_TIME,COUNTRY,ID_COUNT,CLOSE_OUT
0624-209,0,0,6/23/2017,0,0,0,7/27/2017,0,0,0,Plasma Derived Therapy,III,Completed,8,Parexel,69,209,175, Japan,1,34
71102,3,3,3/24/2021,0,0,0,3/24/2021,0,0,0,RGH,III,Execution,34,IQVIA,NULL,465,1166," Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands (the), Norway, Poland, Russian Federation (the), Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,0
71301,3,9,9/9/2020,0,0,0,10/22/2020,0,0,0,RGH,III,Completed,22,IQVIA,NULL,469,546," Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands (the), Norway, Russian Federation (the), Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,43
91301,0,2,2/28/2020,0,0,0,8/31/2020,0,0,0,Plasma Derived Therapy,IV,Completed,55,Synteract,NULL,338,1203," Austria, Belgium, France, Germany, Hungary, Italy, Netherlands (the), Norway, Poland, Portugal, Russian Federation (the), Spain, Sweden, Turkey, United Kingdom of Great Britain and Northern Ireland (the)",1,185
91501,0,2,3/30/2021,0,0,0,5/11/2021,0,0,0,Plasma Derived Therapy,IIIb,Execution,24,IQVIA,462,376,838," Algeria, Croatia, India, Malaysia, North Macedonia, Poland, Romania, Serbia, South Africa, Thailand, Turkey, Ukraine",1,42
10201806002,5,6,8/25/2020,0,0,0,11/19/2020,0,0,0,Oncology,II,Enrollment Complete,35,MEDISCIENCE PLANNING INC,NULL,125,188, Japan,1,86
10201806004,9,9,2/26/2021,0,0,0,4/23/2021,0,0,0,Oncology,II,Enrollment Complete,32,Takeda PRA Development Center,NULL,123,246, Japan,1,56
10201806006,0,1,3/16/2018,0,0,0,5/24/2018,0,0,0,CNS,III,Closed,492,EPS,NULL,105,978, Japan,1,69
10201806007,1,0,4/13/2018,0,0,0,6/18/2018,0,0,0,CNS,I,Closed,56,MEDISCIENCE PLANNING INC,104,51,0, Japan,1,66
10201806013,1,2,8/4/2019,0,0,0,11/1/2019,0,0,0,Oncology,II,Closed,30,EPS,NULL,91,255, Japan,1,89
10201806014,1,1,3/31/2019,0,0,0,5/29/2019,0,0,0,Oncology,I,In Follow-Up,14,Takeda PRA Development Center,NULL,142,483, Japan,1,59
10201806015,6,12,9/30/2020,0,0,0,10/28/2020,0,0,0,Oncology,I,Closed,9,Takeda PRA Development Center,NULL,94,185, Japan,1,28
10201806022,0,0,4/24/2018,0,0,0,6/18/2018,0,0,0,CVM,III,Closed,107,A2 Healthcare,55,166,575, Japan,1,55
10201806025,0,0,2/26/2018,0,0,0,5/29/2018,0,0,0,GI,III,Closed,484,EPS,225,86,430, Japan,1,92
10201806026,1,1,10/30/2018,0,0,0,1/24/2019,0,0,0,GI,I,Closed,552,MEDISCIENCE PLANNING INC,71,94,209, Japan,1,86
10201806027,5,4,8/13/2019,0,0,0,9/30/2019,0,0,0,Marketed Products,III,Closed,30,MEDISCIENCE PLANNING INC,NULL,171,690, Japan,1,48
10201806029,3,4,6/19/2019,0,0,0,2/3/2020,0,0,0,CNS,I,Closed,40,Takeda PRA Development Center,78,44,215, Japan,1,229
10201806030,0,0,10/7/2017,0,0,0,12/15/2017,0,0,0,GI,I,Closed,24,MEDISCIENCE PLANNING INC,93,91,20, Japan,1,69
10201806033,3,2,9/4/2018,0,0,0,10/12/2018,0,0,0,CNS,I,Closed,101,MEDISCIENCE PLANNING INC,61,70,284, Japan,1,38
10201806038,3,4,9/28/2019,0,0,0,1/9/2020,0,0,0,GI,I,Closed,96,Takeda PRA Development Center,83,75,203, Japan,1,103
10201806040,1,1,2/27/2018,0,0,0,8/16/2018,0,0,0,GI,III,Closed,278,MEDISCIENCE PLANNING INC,NULL,94,635, Japan,1,170
10201806041,3,4,7/4/2019,0,0,0,8/9/2019,0,0,0,GI,III,Closed,110,MEDISCIENCE PLANNING INC,NULL,91,962, Japan,1,36
10201806042,0,0,3/11/2018,0,0,0,4/6/2018,0,0,0,Marketed Products,I,Closed,23,MEDISCIENCE PLANNING INC,63,85,6, Japan,1,26
10201806044,13,13,3/31/2021,0,0,0,5/14/2021,0,0,0,Oncology,II,Enrollment Complete,15,MEDISCIENCE PLANNING INC,NULL,70,93, Japan,1,44
10201807001,4,3,10/27/2019,0,0,0,11/22/2019,0,0,0,CNS,I,Closed,54,Takeda PRA Development Center,37,71,301, Japan,1,26
10201810001,0,0,1/10/2021,0,0,0,3/21/2021,0,0,0,Oncology,II,Cancelled,15,TBD,NULL,103,93, Japan,1,70
10201810002,5,5,11/17/2020,0,0,0,12/15/2020,0,0,0,GI,I,Planned,24,Takeda PRA Development Center,54,72,24, Japan,1,28
10201901001,1,3,12/18/2019,0,0,0,2/20/2020,0,0,0,Others,I,Closed,10,PRA,91,100,0, Japan,1,64
10201902001,0,0,4/1/2018,0,0,0,4/1/2018,0,0,0,Oncology,I,Enrolling,14,PPD,54,196,NULL, Japan,1,0
1-1026F0,4,4,5/1/2019,0,0,0,6/28/2019,0,0,0,CNS,IV,Closed,1100,Quintiles,61,114,1167, United States of America (the),1,58
1-106BXY,0,0,4/5/2016,0,0,0,5/2/2016,0,0,0,CNS,I,Closed,10,Quintiles,NULL,273,148," Bulgaria, Netherlands (the), Spain",1,27
1-106C5U,0,0,11/1/2016,0,0,0,12/19/2016,0,0,0,CNS,II,Terminated,36,Quintiles,60,254,260," Czechia, Estonia, Latvia, Russian Federation (the), Spain, United Kingdom of Great Britain and Northern Ireland (the)",1,48
1-106L20,0,0,1/21/2014,0,0,0,3/13/2014,0,0,0,NULL,II,Closed,104,NULL,248,169,501,NULL,1,51
1-10E05V,0,0,1/21/2014,0,0,0,3/13/2014,0,0,0,NULL,II,Closed,104,Quintiles,248,169,501," Belgium, Brazil, Hungary, Italy, Mexico, Poland, Portugal, United States of America (the)",1,51
1-10ELJS,0,0,5/17/2015,0,0,0,6/15/2015,0,0,0,NULL,I,Cancelled,50,NULL,NULL,61,0,NULL,1,29
1-10ELOL,5,6,3/13/2020,0,0,0,5/13/2020,0,0,0,Oncology,I,Closed,80,PPD,27,107,1259, Japan,1,61
1-10ELPN,12,13,12/30/2020,0,0,0,1/29/2021,0,0,0,Oncology,I,Closed,44,PRA,67,229,360, Netherlands (the),1,30
1-10ELQ6,15,17,9/30/2020,0,0,0,11/6/2020,0,0,0,Oncology,I/II,Closed,142,PRA,120,110,881, Japan,1,37
1-10ELUG,0,0,2/4/2020,0,0,0,5/4/2020,0,0,0,Oncology,II,Cancelled,150,NULL,55,120,420,NULL,1,90
1-10ELXD,5,8,2/11/2020,0,0,0,3/17/2020,0,0,0,Oncology,II,Enrollment Complete,60,PRA,108,214,626," Czechia, France, Greece, Netherlands (the), Poland, United States of America (the)",1,35
1-10ELZC,5,8,1/31/2020,0,0,0,4/3/2020,0,0,0,Oncology,I,Closed,46,IQVIA,131,197,518," Japan, Korea (the Republic of)",1,63
1-10FGWP,0,0,3/26/2021,0,0,0,4/25/2021,0,0,0,Oncology,III,Cancelled,300,NULL,56,111,38,NULL,1,30
1-10FGX3,9,12,3/30/2021,0,0,0,5/15/2021,0,0,0,Oncology,II,Completed,122,PRA,379,205,706," Canada, France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,46
1-10FGYU,1,1,4/10/2020,0,0,0,5/10/2020,0,0,0,Oncology,I,Cancelled,45,NULL,NULL,109,150,NULL,1,30
1-10FGZM,5,5,3/22/2021,0,0,0,5/13/2021,0,0,0,Oncology,I,Cancelled,6,PRA,1119,151,235, Netherlands (the),1,52
1-10FH04,0,0,2/23/2021,0,0,0,3/25/2021,0,0,0,Oncology,I,Cancelled,25,NULL,NULL,112,84,NULL,1,30
1-10FH0N,1,1,2/13/2021,0,0,0,3/15/2021,0,0,0,Oncology,I,Cancelled,25,NULL,NULL,109,450,NULL,1,30
1-10FH45,3,3,4/30/2020,0,0,0,8/1/2020,0,0,0,Oncology,I,Cancelled,12,NULL,NULL,122,334,NULL,1,93
1-10FHKN,4,6,2/3/2020,0,0,0,10/30/2020,0,0,0,Oncology,II,Closed,30,IQVIA,NULL,216,365, China,1,270
1-10FL6M,0,0,5/28/2020,0,0,0,6/27/2020,0,0,0,Oncology,II,Cancelled,150,NULL,NULL,206,NULL,NULL,1,30
1-10FLE4,7,9,5/28/2021,0,0,0,7/1/2021,0,0,0,Oncology,III,Enrollment Complete,450,PPD,NULL,169,943," Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea (the Democratic People's Republic of), Mexico, Poland, Russian Federation (the), Spain, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,34
1-10FLEN,7,8,5/4/2021,0,0,0,6/15/2021,0,0,0,Oncology,I,Enrolling,42,PPD,NULL,111,NULL," Spain, United States of America (the)",1,42
1-10FLG7,3,3,12/11/2018,0,0,0,12/25/2018,0,0,0,Oncology,I,Closed,8,PRA,NULL,177,372, Hungary,1,14
1-10XM9M,0,1,11/19/2018,0,0,0,1/17/2019,0,0,0,GI,IV,Closed,300,Hangzhou Tigermed Consulting,55,162,507, China,1,59
1-1146BQ,5,5,7/6/2018,0,0,0,8/17/2018,0,0,0,GI,II,Closed,214,Quintiles,350,223,685," Belgium, Bulgaria, Czechia, Estonia, Poland, United Kingdom of Great Britain and Northern Ireland (the)",1,42
1-1274SY,3,3,4/14/2021,0,0,0,5/14/2021,0,0,0,Oncology,I,Cancelled,6,NULL,NULL,111,180,NULL,1,30
1-12754G,1,1,11/3/2020,0,0,0,1/5/2021,0,0,0,NULL,I,Cancelled,175,PPD,NULL,91,425,NULL,1,63
1-12755U,4,3,6/13/2021,0,0,0,6/14/2021,0,0,0,Oncology,I/II,Execution,125,PPD,NULL,97,499," Canada, China, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,1
1-127563,0,0,10/26/2012,0,0,0,11/25/2012,0,0,0,Oncology,II,Planned,150,PPD,NULL,NULL,690,NULL,1,30
1-127574,0,0,10/21/2013,0,0,0,11/20/2013,0,0,0,Oncology,II,Planned,150,PPD,NULL,155,690,NULL,1,30
1-127596,0,0,12/3/2017,0,0,0,12/31/2017,0,0,0,Oncology,III,Planned,400,PPD,NULL,124,720,NULL,1,28
1-12759X,0,0,11/28/2018,0,0,0,12/26/2018,0,0,0,Oncology,III,Planned,400,PPD,NULL,124,720,NULL,1,28
1-12LDAB,0,0,7/14/2017,0,0,0,8/16/2017,0,0,0,GI,I,Closed,104,PRA,229,201,35, United States of America (the),1,33
1-12MTGF,2,2,3/1/2021,0,0,0,5/31/2021,0,0,0,GI,IV,Enrollment Complete,300,Univ. California San Diego,NULL,66,1391," Canada, United States of America (the)",1,91
1-12MXSR,9,10,9/23/2019,0,0,0,11/18/2019,0,0,0,CNS,I,Closed,114,PPD,NULL,87,1107, United States of America (the),1,56
1-13KZLX,15,20,11/29/2019,0,0,0,4/6/2020,0,0,0,Oncology,II,Enrollment Complete,141,GEICAM,203,184,657," Spain, United States of America (the)",1,129
1-13KZMH,0,0,6/9/2017,0,0,0,7/31/2017,0,0,0,CNS,IV,Closed,352,Quintiles,148,146,139, United States of America (the),1,52
1-13NNMT,6,6,12/28/2020,0,0,0,1/27/2021,0,0,0,Oncology,I,Terminated,1,PRA,90,129,225, Hungary,1,30
1-14MLFD,0,0,9/29/2017,0,0,0,11/20/2017,0,0,0,CNS,I,Cancelled,40,Quintiles,63,117,2,NULL,1,52
1-17J3FB,4,4,10/13/2020,0,0,0,11/17/2020,0,0,0,CNS,IIA,Cancelled,90,PRA,105,776,300,NULL,1,35
1-17VBPS,5,8,11/2/2018,0,0,0,12/28/2018,0,0,0,GI,IB,Closed,24,PRA,58,209,358, United States of America (the),1,56
1-17X9H9,7,9,7/28/2018,0,0,0,11/14/2018,0,0,0,GI,I,Closed,16,PRA,112,985,1, China,1,109
1-17X9HR,10,8,2/25/2021,0,0,0,3/24/2021,0,0,0,GI,III,Enrolling,302,Quintiles,111,776,1317, China,1,27
1-17X9I5,13,13,9/10/2020,0,0,0,1/30/2021,0,0,0,GI,III,Enrollment Complete,204,Quintiles,111,778,540, China,1,142
1-18NLQH,3,2,12/10/2018,0,0,0,2/11/2019,0,0,0,CNS,I,Cancelled,186,PPD,128,42,863, United States of America (the),1,63
1-19NQKS,2,2,1/1/2021,0,0,0,2/5/2021,0,0,0,CNS,II,Cancelled,240,PRA,70,NULL,NULL," Japan, United States of America (the)",1,35
1-1ASDLD,2,3,1/5/2019,0,0,0,3/1/2019,0,0,0,CNS,I,Cancelled,46,PPD,155,631,160, United States of America (the),1,55
1-1BKVJT,2,5,1/21/2020,0,0,0,2/21/2020,0,0,0,Oncology,III,Enrollment Complete,40,PPD,NULL,266,308, Korea (the Republic of),1,31
1-1BKVML,10,12,1/20/2021,0,0,0,2/18/2021,0,0,0,Oncology,I,Execution,22,IQVIA,180,193,872," Japan, Korea (the Republic of)",1,29
1-1BP8VZ,0,0,5/11/2017,0,0,0,5/17/2017,0,0,0,GI,I,Closed,30,Quintiles,1061,274,190, Korea (the Republic of),1,6
1-1CJZC7,8,10,5/21/2020,0,0,0,7/23/2020,0,0,0,GI,III,Cancelled,830,IQVIA,517,1135,988," China, Hong Kong, India, Korea (the Republic of), Malaysia, Philippines (the), Russian Federation (the), Taiwan (Province of China), Thailand",1,63
1-1CJZCH,5,5,6/7/2019,0,0,0,9/5/2019,0,0,0,GI,III,Closed,530,IQVIA,517,1093,695," China, India, Korea (the Democratic People's Republic of), Malaysia, Philippines (the), Russian Federation (the), Taiwan (Province of China)",1,90
1-1CJZCS,0,0,11/9/2016,0,0,0,1/11/2017,0,0,0,CNS,I,Closed,9,PPD,60,98,0, United States of America (the),1,63
1-1DC1ZJ,3,4,5/16/2018,0,0,0,6/7/2018,0,0,0,CNS,I,Closed,40,PRA,247,123,98, United States of America (the),1,22
1-1DC1ZT,5,5,8/7/2020,0,0,0,9/28/2020,0,0,0,CNS,I,Cancelled,30,NULL,63,117,2,NULL,1,52
1-1DC20B,11,8,11/26/2020,0,0,0,1/5/2021,0,0,0,CNS,I,Cancelled,16,PRA,168,99,224, United States of America (the),1,40
1-1DC20E,8,8,5/3/2020,0,0,0,6/22/2020,0,0,0,CNS,I,Cancelled,16,Celerion,63,17,0, United States of America (the),1,50
1-1DUG15,13,8,2/16/2021,0,0,0,4/13/2021,0,0,0,GI,III,Execution,558,PRA,119,154,540," Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea (the Republic of), Norway, Poland, Portugal, Romania, Russian Federation (the), Singapore, Spain, Sweden, Switzerland, Taiwan (Province of China), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,56
1-1DUG1R,5,8,9/18/2020,0,0,0,5/26/2021,0,0,0,GI,III,Planned,460,PRA,119,137,600,NULL,1,250
1-1EIATT,0,0,1/23/2017,0,0,0,3/21/2017,0,0,0,GI,III,Closed,204,Quintiles,NULL,294,279, Russian Federation (the),1,57
1-1EIAU4,0,0,2/17/2017,0,0,0,4/21/2017,0,0,0,GI,III,Closed,150,Quintiles,NULL,358,245, Korea (the Republic of),1,63
1-1EIAUN,0,0,6/5/2017,0,0,0,7/28/2017,0,0,0,GI,III,Closed,204,Quintiles,NULL,371,338, Mexico,1,53
1-1EIAVJ,3,4,12/6/2019,0,0,0,2/7/2020,0,0,0,Oncology,IB,Closed,106,PRA,55,176,1116, United States of America (the),1,63
1-1FFWFN,5,5,5/15/2020,0,0,0,7/10/2020,0,0,0,NULL,III,Planned,288,NULL,70,210,180,NULL,1,56
1-1FFWFY,5,5,5/15/2020,0,0,0,7/10/2020,0,0,0,NULL,III,Planned,288,NULL,70,210,180,NULL,1,56
1-1FFWG7,1,1,4/10/2021,0,0,0,6/4/2021,0,0,0,NULL,III,Planned,600,NULL,132,195,196,NULL,1,55
1-1FQOKZ,3,2,3/23/2021,0,0,0,5/18/2021,0,0,0,CNS,II,Cancelled,15,NULL,57,102,155,NULL,1,56
1-1FQOMT,0,0,8/24/2017,0,0,0,10/19/2017,0,0,0,CNS,I,Closed,12,Quintiles,49,182,131, United Kingdom of Great Britain and Northern Ireland (the),1,56
1-1FQORN,2,2,3/3/2020,0,0,0,4/7/2020,0,0,0,CNS,I,Cancelled,6,NULL,63,NULL,0, United States of America (the),1,35
1-1FQORY,2,2,3/31/2020,0,0,0,5/5/2020,0,0,0,CNS,I,Cancelled,60,NULL,63,NULL,14, United States of America (the),1,35
1-1FQOS7,3,3,10/20/2019,0,0,0,11/22/2019,0,0,0,CNS,I,Cancelled,24,NULL,63,124,2, United States of America (the),1,33
1-1FQOSG,2,2,5/1/2020,0,0,0,6/5/2020,0,0,0,CNS,I,Cancelled,24,NULL,63,NULL,2, United States of America (the),1,35
1-1FQOV2,3,2,2/8/2018,0,0,0,3/30/2018,0,0,0,GI,I,Closed,40,Hangzhou Tigermed Consulting,1211,1105,49, China,1,50
1-1FQOVB,1,2,3/29/2019,0,0,0,4/30/2019,0,0,0,GI,III,Cancelled,450,Hangzhou Tigermed Consulting,1211,763,546,NULL,1,32
1-1FQOVK,4,5,6/14/2018,0,0,0,8/14/2018,0,0,0,GI,III,Closed,200,Hangzhou Tigermed Consulting,1211,764,454,NULL,1,61
1-1GDNNZ,3,4,7/13/2018,0,0,0,10/8/2018,0,0,0,CVM,I,Closed,72,Atlant,177,310,7, Russian Federation (the),1,87
1-1H5VVF,5,5,12/18/2018,0,0,0,1/22/2019,0,0,0,CNS,I,Cancelled,1,PRA,21,60,4, United States of America (the),1,35
1-1H5VVZ,3,3,11/13/2019,0,0,0,1/8/2020,0,0,0,NULL,I,Cancelled,12,NULL,21,62,0,NULL,1,56
1-1HVXQ3,4,1,8/12/2018,0,0,0,9/19/2018,0,0,0,GI,I,Closed,24,Celerion,530,71,0, United States of America (the),1,38
1-1KXHXR,6,6,4/15/2020,0,0,0,6/10/2020,0,0,0,GI,I,Planned,18,NULL,70,102,30,NULL,1,56
1-1KXHY2,1,1,5/13/2017,0,0,0,6/26/2017,0,0,0,GI,I,Closed,52,PRA,130,81,13, United States of America (the),1,44
1-1L0NQP,5,6,7/26/2019,0,0,0,9/20/2019,0,0,0,GI,IIA,Closed,17,Quintiles,76,270,459," Belgium, France, Norway, Sweden, United States of America (the)",1,56
1-1LEUIX,2,2,1/2/2020,0,0,0,2/13/2020,0,0,0,CNS,III,Cancelled,500,PRA,735,150,364,NULL,1,42
1-1M2SHV,4,7,6/26/2020,0,0,0,9/8/2020,0,0,0,Oncology,II/III,Enrollment Complete,120,PPD,NULL,330,592," Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Netherlands (the), Norway, Russian Federation (the), Spain, Sweden, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,74
1-1MI4EK,3,4,4/23/2021,0,0,0,5/23/2021,0,0,0,Oncology,I,Cancelled,30,IQVIA,81,85,12,NULL,1,30
1-1MYTTL,0,14,4/16/2020,0,0,0,6/16/2020,0,0,0,NULL,I,Planned,48,NULL,120,172,505,NULL,1,61
1-1MZ2O7,3,3,10/30/2018,0,0,0,12/5/2018,0,0,0,CNS,IIA,Closed,18,PRA,170,148,303, United States of America (the),1,36
1-1P9TDT,1,1,12/25/2019,0,0,0,2/19/2020,0,0,0,NULL,0,Cancelled,100,NULL,63,91,175,NULL,1,56
1-1S6QUZ,11,12,12/10/2019,0,0,0,2/24/2020,0,0,0,CNS,II,Closed,23,PRA,46,321,533, United Kingdom of Great Britain and Northern Ireland (the),1,76
1-1TM8YR,11,9,6/25/2020,0,0,0,8/20/2020,0,0,0,GI,I,Completed,190,Celerion,420,115,92, United States of America (the),1,56
1-1VZYMN ,2,5,6/15/2018,0,0,0,11/8/2018,0,0,0,GI,I,Closed,6,PRA,92,64,0, Netherlands (the),1,146
1-1VZYNQ ,0,0,7/24/2017,0,0,0,8/28/2017,0,0,0,GI,I,Closed,11,PRA,120,55,0, United States of America (the),1,35
1-1VZYOB,7,8,9/28/2020,0,0,0,10/26/2020,0,0,0,GI,I,Cancelled,36,Celerion,160,616,NULL, United States of America (the),1,28
1-1VZYOK,13,14,8/15/2019,0,0,0,9/6/2019,0,0,0,GI,I,Closed,32,PRA,24,158,603," Czechia, Hungary",1,22
1-1VZYOT,4,5,9/11/2018,0,0,0,10/15/2018,0,0,0,GI,I,Closed,24,PRA,39,200,262," Czechia, Slovakia",1,34
1-1W19RW,5,7,9/15/2019,0,0,0,12/9/2019,0,0,0,GI,IIb,Cancelled,200,PRA,60,225,365," Australia, Canada, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,85
1-1W19SB,1,2,6/15/2021,0,0,0,7/13/2021,0,0,0,GI,I,Planned,24,Celerion,63,121,0,NULL,1,28
1-1W19SY,3,4,6/10/2021,0,0,0,6/18/2021,0,0,0,GI,I,Planned,48,Celerion,63,140,0,NULL,1,8
1-1X3FRR,17,19,2/4/2021,0,0,0,3/25/2021,0,0,0,CNS,II,Completed,40,PRA,43,321,1001," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,49
1-1Y6NEZ,8,10,12/28/2020,0,0,0,5/25/2021,0,0,0,GI,I/II,Completed,80,TFS,0,0,1185," Belgium, France, Lithuania, Spain",1,148
1-1ZTG51,3,3,3/11/2018,0,0,0,7/19/2018,0,0,0,GI,IIA,Closed,48,PRA,162,142,130, United States of America (the),1,130
1-21HO75,0,0,7/11/2017,0,0,0,8/18/2017,0,0,0,GI,I,Closed,12,PRA,27,94,0, United States of America (the),1,38
1-22AXI5,2,2,3/1/2021,0,0,0,4/26/2021,0,0,0,Oncology,I,Enrolling,117,PRA,NULL,186,1149, United States of America (the),1,56
1-22IBXF,16,17,12/30/2020,0,0,0,1/27/2021,0,0,0,Oncology,I,Closed,20,PRA,NULL,254,253, United States of America (the),1,28
1-23H333,0,1,1/21/2021,0,0,0,2/18/2021,0,0,0,GI,I,Planned,24,Celerion,44,NULL,205,NULL,1,28
1-23H33O,0,1,1/26/2021,0,0,0,2/23/2021,0,0,0,GI,I,Planned,24,Celerion,55,121,NULL,NULL,1,28
1-23H347,5,7,3/15/2021,0,0,0,5/11/2021,0,0,0,GI,I,Closed,12,Celerion,56,116,167, United States of America (the),1,57
1-23H34G,13,14,2/19/2021,0,0,0,3/30/2021,0,0,0,GI,I,Completed,6,Celerion,28,83,42, United States of America (the),1,39
1-23H34P,2,7,2/10/2021,0,0,0,3/10/2021,0,0,0,GI,I,Planned,24,Celerion,69,108,NULL,NULL,1,28
1-23H34T,0,1,10/26/2020,0,0,0,12/21/2020,0,0,0,GI,I,Planned,24,Celerion,56,NULL,27,NULL,1,56
1-23H35C,1,2,4/22/2021,0,0,0,5/20/2021,0,0,0,GI,I,Cancelled,24,Celerion,6,NULL,0,NULL,1,28
1-23H35R,6,8,5/18/2021,0,0,0,6/22/2021,0,0,0,GI,I,Planned,24,Celerion,NULL,21,0, United States of America (the),1,35
1-24RE13,9,11,7/12/2019,0,0,0,8/27/2019,0,0,0,GI,IIA,Closed,48,PRA,96,159,522, United States of America (the),1,46
1-24REKY,10,15,2/27/2020,0,0,0,7/30/2020,0,0,0,NULL,I/II,Closed,137,PRA,NULL,85,1022," Spain, United States of America (the)",1,154
1-24RELR,6,9,2/29/2020,0,0,0,6/5/2020,0,0,0,Oncology,II,Closed,222,PRA,0,369,447," Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hong Kong, Italy, Korea (the Republic of), Netherlands (the), Norway, Singapore, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,97
1-24RELX,8,15,11/30/2020,1,0,0,2/1/2021,1,0,0,Oncology,I/II,Enrolling,319,PRA,NULL,208,1779," China, France, Germany, Italy, Japan, Korea (the Democratic People's Republic of), Spain, Taiwan (Province of China), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,63
1-24REM6,1,1,2/1/2020,0,0,0,2/25/2020,0,0,0,Oncology,II,Cancelled,150,NULL,165,120,360,NULL,1,24
1-24REMA,0,0,12/4/2016,0,0,0,6/26/2017,0,0,0,NULL,I,Closed,1,INC Research,NULL,82,191, United States of America (the),1,204
1-24REMU,0,0,11/3/2016,0,0,0,6/26/2017,0,0,0,NULL,I,Closed,1,INC Research,NULL,89,154, United States of America (the),1,235
1-24REN3,15,21,11/30/2020,1,0,0,2/2/2021,1,0,0,Oncology,III,Completed,270,PRA,NULL,231,448," Australia, Austria, Canada, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Korea (the Republic of), Luxembourg, Netherlands (the), Norway, Portugal, Singapore, Spain, Sweden, Switzerland, Taiwan (Province of China), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,64
1-24RENC,10,12,9/3/2019,0,0,0,11/12/2019,0,0,0,Oncology,II,Closed,80,TBD,132,111,678, Japan,1,70
1-24RENV,3,3,9/29/2020,0,0,0,11/18/2020,0,0,0,Oncology,II,Planned,80,NULL,NULL,182,282,NULL,1,50
1-25CUNJ,0,0,10/30/2020,0,0,0,12/25/2020,0,0,0,NULL,II,Planned,250,NULL,154,29,731,NULL,1,56
1-25CUP8,1,2,11/23/2020,0,0,0,1/19/2021,0,0,0,GI,I,Planned,24,PRA,56,114,NULL,NULL,1,57
1-25CUQB,0,1,2/2/2021,0,0,0,3/2/2021,0,0,0,GI,I,Planned,138,NULL,56,NULL,118,NULL,1,28
1-25CUUR,9,7,9/9/2018,0,0,0,10/3/2018,0,0,0,CNS,I,Closed,48,PRA,8,56,344, United States of America (the),1,24
1-25FRSE,6,7,9/3/2019,0,0,0,12/24/2019,0,0,0,NULL,IIIb,Closed,366,Atlant,337,225,214," Belarus, Georgia, Kazakhstan, Russian Federation (the), Ukraine",1,112
1-26JYIY,4,6,9/21/2018,0,0,0,10/22/2018,0,0,0,GI,I,Closed,102,Celerion,530,88,25, United States of America (the),1,31
1-26JYJ8,37,30,7/8/2021,0,0,0,7/14/2021,0,0,0,Oncology,I,Enrollment Complete,20,PRA,77,575,193," France, Italy, Netherlands (the), Spain",1,6
1-26UP5I,10,13,12/15/2019,0,0,0,1/15/2020,0,0,0,GI,0,Closed,20,PRA,71,257,492, United States of America (the),1,31
1-26UPD0,16,13,6/19/2021,1,0,0,7/12/2021,0,0,0,Oncology,III,Enrolling,230,PRA,191,251,897," Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Greece, Hungary, Israel, Italy, Korea (the Republic of), Mexico, New Zealand, Norway, Poland, Romania, Russian Federation (the), Singapore, Slovakia, Spain, Taiwan (Province of China), Turkey, United States of America (the)",1,23
1-26UPF5,4,5,1/30/2019,0,0,0,3/31/2019,0,0,0,Oncology,II,Closed,449,INC Research,NULL,121,396," Australia, Belgium, Canada, France, Germany, Italy, Korea (the Republic of), Netherlands (the), Singapore, Spain, Sweden, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,60
1-26UPFL,3,3,8/30/2018,0,0,0,10/30/2018,0,0,0,Oncology,II,Closed,40,CMIC,NULL,212,450,NULL,1,61
1-26UPFW,10,11,6/30/2021,1,0,0,7/15/2021,1,0,0,Oncology,II,Enrollment Complete,276,PRA,NULL,185,2155," Argentina, Australia, Belgium, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Japan, Korea (the Republic of), Netherlands (the), New Zealand, Norway, Poland, Russian Federation (the), Singapore, Spain, Sweden, Switzerland, Taiwan (Province of China), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,15
1-274PSD,8,10,11/28/2020,0,0,0,3/22/2021,0,0,0,Oncology,III,Enrollment Complete,44,INC Research,NULL,122,778," Argentina, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea (the Democratic People's Republic of), Korea (the Republic of), Netherlands (the), Norway, Poland, Portugal, Romania, Russian Federation (the), Singapore, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland (the)",1,114
1-274PT2,6,7,7/31/2020,0,0,0,9/25/2020,0,0,0,Oncology,I,Planned,24,NULL,28,31,30,NULL,1,56
1-274PTB,12,12,2/14/2021,0,0,0,4/10/2021,0,0,0,Oncology,I,Closed,14,Celerion,223,50,31, United States of America (the),1,55
1-274PTK,8,12,11/9/2019,0,0,0,12/9/2019,0,0,0,Oncology,I,Completed,6,Celerion,140,41,57, United States of America (the),1,30
1-274PTT,11,11,12/1/2020,0,0,0,1/23/2021,0,0,0,Oncology,I,Enrolling,50,PRA,30,93,578, Japan,1,53
1-274PUB,3,3,12/17/2020,0,0,0,2/15/2021,0,0,0,Oncology,I,Cancelled,18,NULL,38,63,350,NULL,1,60
1-274PUK,10,11,5/7/2021,0,0,0,6/4/2021,0,0,0,Oncology,I,Enrolling,16,Celerion,65,253,406, United States of America (the),1,28
1-274PXX,0,0,9/2/2011,0,0,0,10/2/2011,0,0,0,Oncology,I,Planned,40,NULL,30,120,450,NULL,1,30
1-274Q4X,5,6,10/6/2020,0,0,0,11/5/2020,0,0,0,Oncology,I,Closed,28,Celerion,166,120,450, United States of America (the),1,30
1-29750Q,1,1,1/5/2021,0,0,0,3/15/2021,0,0,0,Oncology,II,Cancelled,50,NULL,55,108,546,NULL,1,69
1-2DAR45,3,3,10/6/2019,0,0,0,11/8/2019,0,0,0,CNS,I,Cancelled,36,PRA,56,430,177, United Kingdom of Great Britain and Northern Ireland (the),1,33
1-2GG2AA,3,3,11/7/2018,0,0,0,12/11/2018,0,0,0,CNS,IB,Closed,20,PRA,40,109,81, United States of America (the),1,34
1-2H7217,14,16,3/12/2021,0,0,0,5/11/2021,0,0,0,Oncology,III,Enrolling,246,PRA,NULL,307,98," Argentina, Austria, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Korea (the Republic of), Mexico, Romania, Russian Federation (the), Spain, Sweden, Taiwan (Province of China), Thailand, United States of America (the)",1,60
1-2H721I,14,24,7/6/2020,0,0,0,11/30/2020,0,0,0,Oncology,II,Enrollment Complete,103,PRA,NULL,129,328," Australia, Austria, Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea (the Republic of), Netherlands (the), Spain, Sweden, Taiwan (Province of China), United States of America (the)",1,147
1-2H721R,4,1,5/23/2019,0,0,0,6/17/2019,0,0,0,CNS,I,Closed,48,PRA,46,124,184, United States of America (the),1,25
1-2IFHJV,3,0,8/24/2018,0,0,0,10/5/2018,0,0,0,GI,I,Closed,24,Celerion,NULL,84,0, United States of America (the),1,42
1-2IFHK7,4,4,11/27/2018,0,0,0,12/11/2018,0,0,0,GI,I,Closed,204,Celerion,NULL,98,76, United States of America (the),1,14
1-2J1GSP,8,10,2/1/2019,0,0,0,5/22/2019,0,0,0,Oncology,I,Closed,68,PRA,85,62,254, United States of America (the),1,110
1-2LTMMZ,3,4,5/1/2020,0,0,0,5/29/2020,0,0,0,CNS,I,Cancelled,6,Celerion,NULL,49,126, United States of America (the),1,28
1-2LTMNJ,8,8,11/17/2020,0,0,0,1/12/2021,0,0,0,CNS,I,Planned,32,Celerion,28,NULL,NULL, United States of America (the),1,56
1-2LTMNS,8,8,12/16/2020,0,0,0,2/10/2021,0,0,0,CNS,I,Planned,48,Celerion,28,NULL,NULL, United States of America (the),1,56
1-2LTMO1,4,4,7/22/2019,0,0,0,9/16/2019,0,0,0,CNS,I,Cancelled,24,NULL,31,63,56, Japan,1,56
1-2NGAYV,9,10,3/4/2021,0,0,0,5/19/2021,0,0,0,GI,III,Enrolling,425,PPD,351,621,364, China,1,76
1-2PJ2CV,3,3,5/9/2021,0,0,0,7/8/2021,0,0,0,Oncology,II,Cancelled,50,NULL,55,120,NULL,NULL,1,60
1-2PJ2LB,6,6,9/4/2020,0,0,0,10/4/2020,0,0,0,CNS,IB,Enrolling,16,PPD,54,134,930, United States of America (the),1,30
1-2PZXG5,4,4,10/11/2020,0,0,0,12/4/2020,0,0,0,CNS,II,Cancelled,24,PRA,57,212,382,NULL,1,54
1-2RLYB1,9,10,12/9/2020,0,0,0,1/19/2021,0,0,0,CNS,II,Completed,124,PPD,126,211,630," Australia, Canada, Israel, Poland, Spain, United States of America (the)",1,41
1-2TFPVR,9,13,11/6/2020,0,0,0,2/26/2021,0,0,0,GI,I,Completed,128,PRA,91,87,557, United States of America (the),1,112
1-2TFQBD ,0,1,12/28/2020,0,0,0,2/22/2021,0,0,0,CNS,0,Cancelled,60,NULL,56,252,140,NULL,1,56
1-2TM0AN,7,7,5/16/2021,0,0,0,7/15/2021,0,0,0,Oncology,I,Enrolling,202,PRA,NULL,91,838," Belgium, China, Poland, Romania, Spain, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,60
1-2U8J3J,0,0,9/27/2020,0,0,0,10/30/2020,0,0,0,CNS,II,Cancelled,70,PRA,45,125,679, China,1,33
1-2UGJFT,5,5,11/26/2020,0,0,0,12/24/2020,0,0,0,CNS,III,Planned,400,NULL,49,116,332, United States of America (the),1,28
1-2UGJGD,5,7,5/19/2021,0,0,0,6/16/2021,0,0,0,GI,IIB,Enrolling,180,PRA,71,166,680," Belgium, Germany, United States of America (the)",1,28
1-2UGJKJ,4,4,4/30/2021,0,0,0,6/4/2021,0,0,0,CNS,I,Hold,40,PRA,63,124,30,NULL,1,35
1-2UGJKW,3,4,2/17/2020,0,0,0,3/26/2020,0,0,0,CNS,I,Hold,40,TBD,21,52,0,NULL,1,38
1-2UGJLX,0,0,5/18/2020,0,0,0,6/17/2020,0,0,0,NULL,I,Cancelled,20,NULL,40,120,60,NULL,1,30
1-2UGK0D,1,2,11/6/2018,0,0,0,11/27/2018,0,0,0,CNS,0,Closed,12,NULL,3,60,28, United States of America (the),1,21
1-2V644J,6,6,4/27/2021,0,0,0,6/22/2021,0,0,0,GI,IIB,Cancelled,60,NULL,142,112,180,NULL,1,56
1-2X77JU,1,5,7/30/2019,0,0,0,10/17/2019,0,0,0,CNS,0,Closed,44,PRA,18,103,132, United States of America (the),1,79
1-2YDS7R,2,2,12/3/2020,0,0,0,12/31/2020,0,0,0,CNS,II,Cancelled,52,PRA,34,127,308, United States of America (the),1,28
1-2YLIZL,13,11,2/15/2021,0,0,0,3/15/2021,0,0,0,CNS,II,Completed,30,PPD,74,139,708, United States of America (the),1,28
1-304JYV,1,1,12/6/2018,0,0,0,1/31/2019,0,0,0,GI,0,Completed,14,Parexel,1033,NULL,24, United States of America (the),1,56
1-30EDQR,4,4,9/24/2020,0,0,0,10/22/2020,0,0,0,CNS,II,Cancelled,30,PRA,83,148,331,NULL,1,28
1-30EE6J,3,5,7/11/2019,0,0,0,8/15/2019,0,0,0,CNS,I,Closed,24,PRA,38,109,90," Netherlands (the), United States of America (the)",1,35
1-30EP0F,0,0,2/7/2019,0,0,0,2/26/2019,0,0,0,CNS,0,Cancelled,40,NULL,59,100,84, United States of America (the),1,19
1-30LDVL,2,2,4/20/2020,0,0,0,5/18/2020,0,0,0,GI,I,Cancelled,24,PRA,104,242,65,NULL,1,28
1-31OP17,0,0,1/18/2021,0,0,0,2/15/2021,0,0,0,CNS,II,Cancelled,70,NULL,56,133,364,NULL,1,28
1-32PVRW,8,9,12/30/2020,0,0,0,1/22/2021,0,0,0,GI,I,Planned,160,Celerion,154,492,NULL, United States of America (the),1,23
1-32PVS7,8,9,6/29/2020,0,0,0,8/12/2020,0,0,0,CNS,I,Completed,160,PRA,42,71,375, United States of America (the),1,44
1-33RHUL,3,3,5/5/2021,0,0,0,6/24/2021,0,0,0,CNS,I,Cancelled,24,NULL,63,161,56,NULL,1,50
1-3414NB,4,4,4/28/2021,0,0,0,5/26/2021,0,0,0,Oncology,I,Planned,12,Celerion,130,NULL,0,NULL,1,28
1-34Q1ZH,1,1,11/14/2019,0,0,0,12/12/2019,0,0,0,NULL,I,Cancelled,228,NULL,60,28,126,NULL,1,28
1-34WP2F,4,3,6/3/2021,0,0,0,6/10/2021,0,0,0,CNS,II,Cancelled,80,PPD,70,633,NULL,NULL,1,7
1-34WP2Q,2,2,5/12/2019,0,0,0,6/14/2019,0,0,0,GI,I,Closed,6,Celerion,50,49,31, United States of America (the),1,33
1-34WP30 ,1,0,3/18/2019,0,0,0,4/15/2019,0,0,0,GI,I,Closed,120,Celerion,18,42,22,NULL,1,28
1-359QOT,7,8,10/28/2020,0,0,0,2/16/2021,0,0,0,CNS,II,Completed,24,PRA,72,181,229, United Kingdom of Great Britain and Northern Ireland (the),1,111
1-359QPS,1,1,8/25/2020,0,0,0,10/20/2020,0,0,0,NULL,I,Cancelled,81,NULL,42,56,310,NULL,1,56
1-36QQJG,0,0,3/9/2021,0,0,0,4/6/2021,0,0,0,CNS,I,Planned,12,NULL,28,72,34,NULL,1,28
1-37HZ3U,1,1,3/4/2021,0,0,0,4/1/2021,0,0,0,CNS,II,Cancelled,90,IQVIA,51,133,364, China,1,28
1-382WX7,2,7,6/25/2020,0,0,0,9/23/2020,0,0,0,CNS,I,Closed,6,Celerion,NULL,55,120, United States of America (the),1,90
1-39F7HP,2,2,2/23/2021,0,0,0,3/30/2021,0,0,0,CNS,II,Planned,72,INC Research,105,78,74,NULL,1,35
1-39F7S9,0,0,11/5/2020,0,0,0,12/10/2020,0,0,0,CNS,II,Cancelled,48,TBD,84,NULL,240,NULL,1,35
1-39REHV,1,3,12/3/2019,0,0,0,1/24/2020,0,0,0,CNS,I,Closed,16,Celerion,50,56,32, United States of America (the),1,52
1-39REQR,5,5,1/11/2021,0,0,0,2/9/2021,0,0,0,CNS,I,Cancelled,152,PRA,185,444,NULL,NULL,1,29
1-3A58OZ,10,9,7/2/2021,0,0,0,7/15/2021,0,0,0,CNS,Ib,Completed,40,IQVIA,36,220,466," Japan, United States of America (the)",1,13
1-3A58P8,5,5,6/22/2020,0,0,0,7/20/2020,0,0,0,CNS,II,Closed,42,IQVIA,22,133,150, United States of America (the),1,28
1-3BD3YR,2,2,11/19/2019,0,0,0,1/6/2020,0,0,0,GI,I,Closed,12,Celerion,72,35,7, United States of America (the),1,48
1-3BD4B4,0,0,5/30/2015,0,0,0,8/10/2015,0,0,0,CNS,II,Cancelled,300,TBD,42,NULL,NULL,NULL,1,72
1-3CYXNM,0,0,7/14/2020,0,0,0,8/11/2020,0,0,0,CNS,I,Cancelled,8,Celerion,14,56,1,NULL,1,28
1-3CYXQQ,0,0,9/8/2020,0,0,0,10/6/2020,0,0,0,CNS,I,Planned,40,NULL,42,79,0,NULL,1,28
1-3CYXR9,0,0,4/9/2016,0,0,0,6/3/2016,0,0,0,CNS,I,Planned,40,NULL,42,NULL,90,NULL,1,55
1-3CYXSK,1,0,6/24/2016,0,0,0,10/9/2017,0,0,0,CNS,I,Planned,24,NULL,NULL,NULL,100,NULL,1,472
1-3CYXSU,0,0,9/1/2015,0,0,0,10/7/2015,0,0,0,CNS,I,Planned,36,Celerion,24,71,7, United States of America (the),1,36
1-3CYXTC,0,0,11/6/2020,0,0,0,12/11/2020,0,0,0,CNS,I,Planned,24,NULL,63,NULL,28,NULL,1,35
1-3CYXTV,0,0,9/21/2016,0,0,0,10/26/2016,0,0,0,CNS,I,Cancelled,24,TBD,82,92,84,NULL,1,35
1-3CYXU4,0,0,9/21/2016,0,0,0,10/26/2016,0,0,0,CNS,I,Cancelled,32,TBD,82,92,84,NULL,1,35
1-3CYXU9,0,0,9/1/2015,0,0,0,10/7/2015,0,0,0,CNS,I,Planned,36,Celerion,24,71,7, United States of America (the),1,36
1-3CYXUI,0,0,8/9/2015,0,0,0,9/14/2015,0,0,0,CNS,I,Planned,36,Celerion,24,71,7, United States of America (the),1,36
1-3CYXUN,0,0,9/21/2016,0,0,0,10/26/2016,0,0,0,CNS,I,Cancelled,12,TBD,82,92,84,NULL,1,35
1-3CYXUW,0,0,9/21/2016,0,0,0,10/26/2016,0,0,0,CNS,I,Planned,48,NULL,82,92,84,NULL,1,35
1-3CYXVW,0,0,9/1/2015,0,0,0,10/7/2015,0,0,0,CNS,I,Planned,20,Celerion,24,71,7, United States of America (the),1,36
1-3CYXWK,1,1,8/12/2020,0,0,0,9/9/2020,0,0,0,CNS,I,Cancelled,96,PRA,63,112,153,NULL,1,28
1-3CYXXD,7,5,9/22/2020,0,0,0,10/27/2020,0,0,0,CNS,I,Planned,16,Celerion,105,72,0,NULL,1,35
1-3CYXY6,0,0,8/27/2019,0,0,0,10/16/2019,0,0,0,CNS,I,Planned,50,TBD,0,NULL,14,NULL,1,50
1-3CYXYF,0,0,10/2/2020,0,0,0,11/23/2020,0,0,0,CNS,I,Planned,40,TBD,0,NULL,462,NULL,1,52
1-3CYXYO,0,0,4/17/2021,0,0,0,6/7/2021,0,0,0,CNS,I,Planned,48,NULL,NULL,NULL,16,NULL,1,51
1-3CYXZG,0,0,1/27/2014,0,0,0,3/4/2014,0,0,0,CNS,III,Planned,48,NULL,NULL,106,NULL,NULL,1,36
1-3CYY1G,0,0,3/9/2021,0,0,0,4/6/2021,0,0,0,CNS,I,Planned,16,NULL,28,72,NULL,NULL,1,28
1-3D8NXB,14,13,3/3/2021,0,0,0,6/14/2021,0,0,0,GI,I,Completed,42,Precision for Medicine,28,98,317, United States of America (the),1,103
1-3D8NXM,2,0,6/4/2021,0,0,0,6/22/2021,0,0,0,RGH,I,Start Up,36,PPD,223,445,213," Belgium, Canada, Italy, Poland, Serbia, Spain, United States of America (the)",1,18
1-3D8O5D,0,0,3/1/2021,0,0,0,4/19/2021,0,0,0,CNS,IB,Planned,28,NULL,42,63,180,NULL,1,49
1-3DYC4G,6,3,6/26/2021,0,0,0,7/15/2021,0,0,0,CNS,I,Planned,6,Celerion,28,NULL,26,NULL,1,19
1-3DYC4P,1,1,2/27/2021,0,0,0,4/23/2021,0,0,0,CNS,I,Planned,16,NULL,28,NULL,30,NULL,1,55
1-3DYC4Y,9,10,5/31/2021,0,0,0,6/21/2021,0,0,0,CNS,I,Execution,54,Celerion,59,83,40, United States of America (the),1,21
1-3DYCDM,11,12,5/16/2021,0,0,0,6/25/2021,0,0,0,GI,I,Completed,40,Celerion,91,147,191, United States of America (the),1,40
1-3DYCND,1,1,12/18/2020,0,0,0,1/15/2021,0,0,0,GI,I,Cancelled,24,NULL,NULL,56,17,NULL,1,28
1-3DYCNO,1,1,12/18/2020,0,0,0,1/15/2021,0,0,0,GI,I,Cancelled,100,NULL,132,113,203,NULL,1,28
1-3DYCO1,0,0,4/12/2021,0,0,0,5/10/2021,0,0,0,GI,I,Cancelled,24,NULL,NULL,56,29,NULL,1,28
1-3ELU49,3,3,4/14/2020,0,0,0,6/10/2020,0,0,0,CNS,I,Closed,16,Celerion,60,62,13, United States of America (the),1,57
1-3ELU4K,5,4,6/10/2021,0,0,0,7/8/2021,0,0,0,CNS,I,Planned,32,NULL,49,148,0,NULL,1,28
1-3ELU4T,0,0,12/24/2020,0,0,0,2/18/2021,0,0,0,CNS,I,Planned,24,NULL,42,63,104,NULL,1,56
1-3ELU52,1,1,4/8/2021,0,0,0,5/27/2021,0,0,0,CNS,I,Planned,24,NULL,42,63,31,NULL,1,49
1-3ELU5B,3,3,4/19/2021,0,0,0,6/14/2021,0,0,0,CNS,I,Planned,24,PRA,42,63,13,NULL,1,56
1-3ELUA3,1,1,5/14/2021,0,0,0,6/11/2021,0,0,0,NULL,IB,Cancelled,30,NULL,25,NULL,120,NULL,1,28
1-3G1MUN,11,8,5/4/2021,0,0,0,6/10/2021,0,0,0,CNS,0,Completed,32,IQVIA,63,165,266, United States of America (the),1,37
1-3HUR3B,0,0,5/18/2021,0,0,0,7/13/2021,0,0,0,GI,III,Cancelled,200,Quintiles,330,188,NULL,NULL,1,56
1-3ILKVN,0,0,5/9/2021,0,0,0,7/4/2021,0,0,0,Oncology,IB,Enrolling,228,PPD,NULL,178,238," Brazil, China, France, Japan, Poland, Ukraine, United States of America (the)",1,56
1-3LQ411,1,4,11/17/2020,0,0,0,3/18/2021,0,0,0,CNS,I,Closed,32,PRA,67,122,41, Japan,1,121
1-3S3AWP,0,0,11/27/2020,1,0,0,2/19/2021,0,0,0,NULL,IB,Planned,40,PPD,9,106,102,NULL,1,84
1-3SDL33,6,6,12/31/2020,0,0,0,2/12/2021,0,0,0,CNS,I,Closed,18,PRA,70,65,55, United States of America (the),1,43
1-3T436Z,0,0,10/7/2020,0,0,0,11/4/2020,0,0,0,GI,I,Planned,25,NULL,42,112,85,NULL,1,28
1-3TL6IT,0,0,4/22/2021,0,0,0,5/20/2021,0,0,0,GI,I,Planned,40,NULL,6,123,0,NULL,1,28
1-3ZP5KE,0,0,12/6/2006,0,0,0,1/31/2007,0,0,0,Oncology,I/II,Planned,36,TBD,NULL,NULL,NULL, Japan,1,56
161504,0,0,1/15/2021,0,0,0,6/1/2021,0,0,0,Plasma Derived Therapy,IV,Execution,40,IQVIA,0,249,870," Czechia, Denmark, France, Greece, Hungary, Slovakia, Sweden, United Kingdom of Great Britain and Northern Ireland (the)",1,137
1-8R8L,3,4,10/31/2017,0,0,0,1/29/2018,0,0,0,GI,III,Closed,2200,Quintiles,NULL,330,1230," Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Korea (the Republic of), Latvia, Malaysia, Malta, Netherlands (the), New Zealand, Norway, Poland, Portugal, Romania, Russian Federation (the), Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,90
1-8ULV,1,1,5/23/2017,0,0,0,6/30/2017,0,0,0,NULL,I,Closed,63,Quintiles,NULL,147,980, United States of America (the),1,38
1-8UMZ,5,5,2/21/2018,0,0,0,3/19/2018,0,0,0,Oncology,I/II,Closed,61,PPD,NULL,180,463, United States of America (the),1,26
1-8UNO,1,0,12/29/2016,0,0,0,5/3/2017,0,0,0,Oncology,I/II,Closed,61,PPD,NULL,187,1057," Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Russian Federation (the), Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,125
1-8UOZ,3,5,11/13/2018,0,0,0,12/13/2018,0,0,0,Oncology,I,Closed,32,ICON,NULL,261,567," Argentina, Canada, France, Germany, Greece, Hungary, Italy, Netherlands (the), Norway, Spain, Sweden, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,30
1-8UPO,2,3,11/27/2017,0,0,0,10/1/2018,0,0,0,Oncology,I/II,Closed,60,PPD,NULL,252,343, United States of America (the),1,308
1-8VE85,0,0,2/15/2012,0,0,0,3/16/2012,0,0,0,NULL,I,Closed,89,PPD,NULL,139,1297, United States of America (the),1,30
1-8VE8X,0,0,7/15/2013,0,0,0,9/30/2013,0,0,0,Oncology,I,Closed,99,PPD,NULL,146,1737, United States of America (the),1,77
1-8VEAE,0,0,8/25/2013,0,0,0,10/28/2013,0,0,0,NULL,I,Closed,72,PPD,NULL,105,1305, United States of America (the),1,64
1-8VEAZ,1,0,5/22/2012,0,0,0,8/17/2012,0,0,0,NULL,I,Closed,66,PPD,NULL,83,785, United States of America (the),1,87
1-994OP,4,4,2/27/2019,0,0,0,4/28/2019,0,0,0,Oncology,III,Enrollment Complete,248,PPD,NULL,215,2706," Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea (the Republic of), Netherlands (the), Norway, Singapore, Spain, Sweden, Switzerland, Taiwan (Province of China), Thailand, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,60
1-9GYS5,2,3,4/12/2018,0,0,0,6/4/2018,0,0,0,Oncology,I/II,Closed,42,ICON,NULL,280,1457," France, Germany, Italy, Mexico, Netherlands (the), Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,53
1-9H28T,3,3,1/28/2021,0,0,0,5/12/2021,0,0,0,Oncology,III,Enrollment Complete,1334,ICON,NULL,108,1150," Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, France, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea (the Republic of), Mexico, Netherlands (the), New Zealand, Norway, Peru, Poland, Romania, Russian Federation (the), Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Thailand, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,104
1-9HF2D,7,9,9/30/2020,1,1,0,11/6/2020,1,1,0,Oncology,III,Enrollment Complete,722,PPD,NULL,189,637," Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Korea (the Republic of), Mexico, Netherlands (the), New Zealand, Poland, Portugal, Romania, Russian Federation (the), Singapore, Spain, Sweden, Taiwan (Province of China), Thailand, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,37
1-9I7GV,2,2,12/15/2017,0,0,0,2/5/2018,0,0,0,Oncology,III,Closed,354,Quintiles,NULL,322,877," Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea (the Republic of), Lebanon, Lithuania, Malaysia, Mexico, Netherlands (the), New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russian Federation (the), Saudi Arabia, Serbia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan (Province of China), Thailand, Turkey, Ukraine, United Arab Emirates (the), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,52
1-9KB55,0,0,12/18/2012,0,0,0,1/17/2013,0,0,0,NULL,I,Closed,218,Hammersmith Medicines Research,NULL,18,347, United Kingdom of Great Britain and Northern Ireland (the),1,30
1-ACL3H,1,1,4/4/2017,0,0,0,5/15/2017,0,0,0,Oncology,I,Closed,24,PPD,NULL,311,547," Hong Kong, Korea (the Republic of), Singapore",1,41
1-CJRPD,10,12,2/7/2019,0,0,0,5/9/2019,0,0,0,Oncology,I,Closed,170,Synteract,NULL,49,1865," Spain, United States of America (the)",1,91
1-CK4HM,2,4,12/31/2017,0,0,0,3/4/2018,0,0,0,Oncology,I,Closed,95,Sarah Cannon Research Institut,NULL,48,875, United States of America (the),1,63
1-CP5PJ,7,12,2/28/2021,1,0,0,5/20/2021,1,0,0,Oncology,III,Enrollment Complete,701,PPD,NULL,92,958," Belgium, Canada, France, Japan, Korea (the Republic of), New Zealand, Russian Federation (the), United States of America (the)",1,81
1-DT93H,1,1,11/18/2016,0,0,0,1/25/2017,0,0,0,Oncology,I,Closed,40,ICON,NULL,336,511," Canada, United States of America (the)",1,68
1-EEZ99,1,2,3/23/2017,0,0,0,6/12/2017,0,0,0,Oncology,II,Closed,44,PPD,NULL,179,731," Belgium, Canada, Italy, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,81
1-EGKBL,4,4,11/30/2018,0,0,0,1/15/2019,0,0,0,Oncology,I,Closed,64,PPD,NULL,186,959, United States of America (the),1,46
1-F28N,0,0,4/20/2012,0,0,0,5/24/2012,0,0,0,Oncology,I,Closed,116,Dobbs Consulting,NULL,79,1042," Canada, United States of America (the)",1,34
1-F29M,1,0,10/20/2014,0,0,0,12/20/2014,0,0,0,Oncology,I,Closed,34,Dobbs Consulting,NULL,175,1138," Canada, United States of America (the)",1,61
1-F2HL,2,4,7/27/2018,0,0,0,10/17/2018,0,0,0,Oncology,III,Closed,136,ICON,NULL,202,1082," Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands (the), Peru, Poland, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,82
1-F2HY,1,1,3/30/2018,0,0,0,5/18/2018,0,0,0,Oncology,I,Closed,150,Quintiles,NULL,70,1842," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,49
1-F6HHL,7,7,12/30/2019,0,0,0,2/28/2020,0,0,0,Oncology,IV,Closed,NULL,IQVIA,NULL,377,1658," Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands (the), Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland (the)",1,60
1-F9CI7,0,0,6/16/2015,0,0,0,8/14/2015,0,0,0,Oncology,I,Closed,20,ICON,NULL,366,138," Belgium, Lithuania, Netherlands (the), Spain, United Kingdom of Great Britain and Northern Ireland (the)",1,59
1-F9CII,3,3,5/4/2021,0,0,0,6/25/2021,0,0,0,Oncology,IV,Enrollment Complete,49,Quintiles,NULL,427,2099," Australia, Belgium, Bulgaria, Croatia, Czechia, Hungary, Israel, Poland, Portugal, Romania, Russian Federation (the), South Africa, Spain, Turkey, United Kingdom of Great Britain and Northern Ireland (the)",1,52
1-G14DR,3,4,5/21/2018,0,0,0,6/26/2018,0,0,0,Oncology,I,Closed,64,Quintiles,NULL,115,672, United States of America (the),1,36
1-GG0OZ,3,4,6/30/2018,0,0,0,9/1/2018,0,0,0,Oncology,I,Closed,101,Quintiles,NULL,118,1181," Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,63
1-HC2H3,1,0,3/25/2015,0,0,0,5/19/2015,0,0,0,Oncology,I,Closed,45,PPD,NULL,130,513, United States of America (the),1,55
1-HRYDH,1,0,9/30/2015,0,0,0,6/20/2017,0,0,0,Oncology,I,Cancelled,20,PPD,NULL,644,90, United States of America (the),1,629
1-HTT6P,1,2,3/11/2020,0,0,0,5/30/2020,0,0,0,Oncology,IV,Closed,60,IQVIA,NULL,253,355," Belgium, Czechia, Germany, Hungary, Israel, Korea (the Democratic People's Republic of), Lithuania, Malaysia, Poland, Portugal, Russian Federation (the), Spain, Taiwan (Province of China), Thailand, Turkey, Ukraine, United States of America (the)",1,80
1-HTWUL,0,0,1/31/2016,0,0,0,4/8/2016,0,0,0,Oncology,II,Closed,166,Quintiles,NULL,238,506," Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United States of America (the)",1,68
1-HXXOT,0,1,11/9/2016,0,0,0,2/27/2017,0,0,0,Oncology,I,Cancelled,119,PPD,NULL,180,798," France, United States of America (the)",1,110
1-IDSVB,5,12,5/30/2019,0,0,0,8/1/2019,0,0,0,Oncology,I,Execution,182,IQVIA,NULL,93,1753," Belgium, Canada, Germany, Italy, Moldova (the Republic of), Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,63
1-INX3G,6,7,6/29/2018,0,0,0,7/31/2018,0,0,0,Oncology,II,Closed,148,PPD,NULL,232,434," Australia, Denmark, Greece, Hungary, New Zealand, Poland, Sweden, United States of America (the)",1,32
1-JLM1X,9,10,1/5/2019,0,0,0,3/9/2019,0,0,0,Oncology,I/II,Closed,118,Quintiles,74,164,1415," Belgium, France, United States of America (the)",1,63
1-L6PF9,2,1,3/7/2017,0,0,0,5/24/2017,0,0,0,Oncology,II,Closed,125,Quintiles,NULL,135,308," Canada, United States of America (the)",1,78
1-L7IAF,9,11,2/28/2019,0,0,0,3/25/2019,0,0,0,Oncology,I,Closed,30,Quintiles,NULL,88,331, United States of America (the),1,25
1-LSEIL,1,0,12/14/2015,0,0,0,3/28/2016,0,0,0,Oncology,II,Closed,100,Quintiles,NULL,144,293," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,105
1-MGEGX,0,0,6/5/2017,0,0,0,8/28/2017,0,0,0,Oncology,I,Closed,52,PPD,NULL,99,797, United States of America (the),1,84
1-N61SX,0,0,4/19/2014,0,0,0,5/27/2014,0,0,0,NULL,I,Closed,40,In-House,NULL,82,0, United States of America (the),1,38
1-O0YDZ,5,7,12/31/2020,0,0,0,3/19/2021,0,0,0,Oncology,I/II,Enrollment Complete,67,Quintiles,NULL,445,730," Belgium, Brazil, Czechia, Hong Kong, Italy, Japan, Singapore, Spain, Taiwan (Province of China), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,78
1-O1BUN,6,6,8/12/2019,0,0,0,1/30/2021,0,0,0,Oncology,III,Enrollment Complete,706,PPD,NULL,220,1287," Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea (the Republic of), Mexico, Poland, Portugal, Russian Federation (the), Serbia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Thailand, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,537
1-OH0VT,0,0,10/23/2015,0,0,0,3/28/2016,0,0,0,Oncology,II,Cancelled,38,IQVIA,NULL,159,301," Belgium, Brazil, Italy, Peru, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,157
1-OH0W6,0,0,11/13/2015,0,0,0,4/27/2016,0,0,0,Oncology,II,Cancelled,43,IQVIA,NULL,229,259," Belgium, Brazil, Italy, Peru, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,166
1-OMAA5,7,6,3/15/2021,0,0,0,4/14/2021,0,0,0,Oncology,III,Enrollment Complete,115,PPD,NULL,160,363, China,1,30
1-P2K8B,0,0,10/8/2015,0,0,0,1/12/2016,0,0,0,Oncology,I/II,Cancelled,95,IQVIA,NULL,249,143," Japan, Korea (the Democratic People's Republic of), Taiwan (Province of China)",1,96
1-P37UL,2,3,9/30/2019,0,0,0,3/30/2020,0,0,0,Oncology,IB,Closed,81,Quintiles,NULL,NULL,1518," France, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,182
1-QCXSG,15,22,10/30/2020,0,0,0,2/8/2021,0,0,0,Oncology,II,Closed,242,PRA,412,485,768," Australia, Belgium, Canada, France, Germany, Italy, Netherlands (the), Norway, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,101
1-RP5YP,8,9,9/4/2019,0,0,0,10/30/2019,0,0,0,Oncology,II,Enrollment Complete,120,PPD,NULL,414,433," Belgium, Brazil, Bulgaria, Canada, Czechia, France, Germany, Ireland, Israel, Italy, Netherlands (the), Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,56
1-U0EGW,2,4,6/29/2018,0,0,0,9/1/2018,0,0,0,Oncology,I,Closed,56,Sarah Cannon Research Institut,NULL,167,330, United States of America (the),1,64
1-V5BIE,0,0,2/17/2017,0,0,0,3/31/2017,0,0,0,Oncology,IB,Closed,178,Quintiles,NULL,124,275," Belgium, Italy, Poland, Spain, United States of America (the)",1,42
1-Z9VLF,6,7,3/26/2021,0,0,0,5/13/2021,0,0,0,CNS,III,Cancelled,550,IQVIA,167,122,729, Canada,1,48
1-Z9VMJ,0,0,3/3/2020,0,0,0,4/21/2020,0,0,0,CNS,III,Cancelled,550,PRA,70,154,NULL,NULL,1,49
1-ZA6U1,2,2,8/8/2019,0,0,0,9/26/2019,0,0,0,CNS,III,Closed,3500,Quintiles,295,201,845," Australia, Germany, Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,49
1-ZA6UB,0,0,12/18/2014,0,0,0,3/18/2015,0,0,0,CNS,III,Closed,675,Covance,295,176,356," Italy, Russian Federation (the), Switzerland",1,90
1-ZA6UK,1,1,5/9/2018,0,0,0,9/25/2018,0,0,0,CNS,III,Closed,149,Quintiles,425,323,1638," Australia, Germany, Ireland, Italy, Russian Federation (the), Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,139
1-ZA6W2,0,0,3/2/2015,0,0,0,3/4/2015,0,0,0,CNS,I,Closed,11,In-House,27,56,120, United States of America (the),1,2
1-ZA6WK,0,0,4/13/2015,0,0,0,6/2/2015,0,0,0,CNS,I,Closed,36,PPD,113,78,6, United States of America (the),1,50
1-ZA6WT,0,0,5/4/2015,0,0,0,6/19/2015,0,0,0,CNS,I,Closed,36,PPD,109,54,21, United States of America (the),1,46
1-ZA6X2,0,0,10/1/2015,0,0,0,11/9/2015,0,0,0,CNS,I,Closed,76,PPD,105,122,20, United States of America (the),1,39
1-ZA6XK,0,0,9/28/2015,0,0,0,11/4/2015,0,0,0,CNS,II,Closed,200,PPD,146,102,419, United States of America (the),1,37
1-ZA6XT,0,0,11/16/2015,0,0,0,12/23/2015,0,0,0,CNS,III,Closed,1750,PPD,119,111,455, United States of America (the),1,37
1-ZA6YK,2,3,9/30/2018,0,0,0,1/30/2019,0,0,0,GI,IV,Closed,100,Hangzhou Tigermed Consulting,55,257,463, China,1,122
1-ZA6ZB,0,1,11/22/2016,0,0,0,1/24/2017,0,0,0,CNS,II,Closed,108,Quintiles,158,433,373," Argentina, Brazil, Bulgaria, Canada, Colombia, Czechia, Germany, Japan, Korea (the Republic of), Mexico, Peru, Poland, Russian Federation (the), Spain, United Kingdom of Great Britain and Northern Ireland (the)",1,63
1-ZA70B,9,9,11/6/2020,0,0,0,1/1/2021,0,0,0,GI,II,Closed,80,PRA,794,420,907," Belgium, Canada, France, Germany, Hungary, Israel, Netherlands (the), Poland, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,56
1-ZA71B,4,5,1/19/2019,0,0,0,3/15/2019,0,0,0,GI,IIIB,Closed,758,Quintiles,77,133,810," Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea (the Republic of), Latvia, Lithuania, Mexico, Netherlands (the), Poland, Portugal, Romania, Russian Federation (the), Serbia, Slovakia, Spain, Taiwan (Province of China), Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,55
1-ZA71K,3,7,3/7/2018,0,0,0,5/2/2018,0,0,0,GI,IIIB,Closed,100,Quintiles,140,131,597," Belgium, Canada, Czechia, France, Hungary, Italy, Poland, United States of America (the)",1,56
1-ZA722,6,8,9/19/2018,0,0,0,11/30/2018,0,0,0,GI,III,Closed,400,Quintiles,77,315,509," Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, Japan, Korea (the Republic of), Lithuania, Mexico, Netherlands (the), Poland, Romania, Russian Federation (the), Serbia, Slovakia, Spain, Sweden, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,72
1-ZA72B,9,12,4/23/2021,1,1,1,5/26/2021,1,1,1,GI,IIIB,Enrollment Complete,746,Quintiles,77,414,1161," Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, Japan, Korea (the Republic of), Lithuania, Mexico, Netherlands (the), Poland, Romania, Russian Federation (the), Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan (Province of China), Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,33
1-ZA72K,12,19,10/11/2019,0,0,0,10/11/2019,0,0,0,GI,III,Closed,645,Quintiles,77,311,900," Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, Japan, Korea (the Republic of), Lithuania, Mexico, Netherlands (the), Poland, Romania, Russian Federation (the), Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan (Province of China), Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,0
1-ZA774,0,0,7/22/2018,0,0,0,9/10/2018,0,0,0,CNS,I,Cancelled,6,NULL,63,115,0,NULL,1,50
1-ZA77D,0,0,12/6/2018,0,0,0,1/25/2019,0,0,0,CNS,I,Cancelled,70,NULL,63,115,14,NULL,1,50
1-ZA77M,0,0,5/16/2021,0,0,0,7/5/2021,0,0,0,CNS,I,Cancelled,24,NULL,63,117,2,NULL,1,50
1-ZA790,0,0,5/16/2021,0,0,0,7/5/2021,0,0,0,CNS,I,Cancelled,24,NULL,63,117,2,NULL,1,50
1-ZA79J,0,0,5/17/2020,0,0,0,7/10/2020,0,0,0,CNS,II,Cancelled,320,NULL,167,120,900,NULL,1,54
1-ZA7F5,0,0,11/17/2018,0,0,0,1/11/2019,0,0,0,CNS,I,Cancelled,36,NULL,NULL,32,59,NULL,1,55
1-ZD0NM,0,0,6/9/2016,0,0,0,10/12/2016,0,0,0,CNS,I,Closed,120,Quintiles,127,83,238, United Kingdom of Great Britain and Northern Ireland (the),1,125
1-ZD0OZ,0,0,8/30/2016,0,0,0,11/16/2016,0,0,0,CNS,I,Closed,22,Quintiles,148,133,120, United Kingdom of Great Britain and Northern Ireland (the),1,78
1-ZD0Q2,5,7,2/27/2019,0,0,0,4/10/2019,0,0,0,CNS,II,Closed,65,Quintiles,54,229,363, United States of America (the),1,42
1-ZD0RB,0,0,9/19/2019,0,0,0,10/31/2019,0,0,0,CNS,III,Cancelled,500,NULL,312,266,364,NULL,1,42
1-ZD0ST,9,11,3/11/2021,0,0,0,6/4/2021,0,0,0,CNS,II,Completed,234,IQVIA,47,125,1046," Czechia, Germany, Italy, Poland, Russian Federation (the), Serbia, Spain, Ukraine, United States of America (the)",1,85
1-ZD0TN,0,0,11/11/2019,0,0,0,12/16/2019,0,0,0,CNS,I,On Hold,52,NULL,NULL,109,805,NULL,1,35
1-ZD0U6,7,7,4/19/2021,0,0,0,5/17/2021,0,0,0,CNS,I,Planned,24,Celerion,28,NULL,NULL,NULL,1,28
1-ZD0UF,7,7,9/23/2019,0,0,0,11/18/2019,0,0,0,CNS,I,Closed,16,Celerion,52,95,84, United States of America (the),1,56
1-ZD0UY,0,0,5/24/2017,0,0,0,7/24/2017,0,0,0,CNS,I,Closed,16,PRA,40,64,7, United States of America (the),1,61
1-ZD7VH,0,0,11/22/2013,0,0,0,3/10/2014,0,0,0,CVM,I,Closed,48,Covance,NULL,354,1466,NULL,1,108
1-ZD7WM,0,0,10/21/2019,0,0,0,1/27/2020,0,0,0,NULL,IIIB,Cancelled,300,NULL,418,92,1075,NULL,1,98
1-ZD7XO,0,0,10/5/2015,0,0,0,6/29/2016,0,0,0,CVM,III,Closed,659,Covance,142,781,540," China, Korea (the Republic of), Malaysia, Taiwan (Province of China)",1,268
1-ZD7XX,0,0,4/27/2016,0,0,0,6/15/2016,0,0,0,CVM,I,Closed,24,PPD,125,422,7, Russian Federation (the),1,49
1-ZD7ZJ,0,0,8/28/2014,0,0,0,8/13/2015,0,0,0,CNS,I,Closed,27,Covance,276,130,350, United States of America (the),1,350
1-ZD7ZX,0,0,3/12/2014,0,0,0,6/12/2014,0,0,0,CNS,I,Closed,18,Covance,209,148,141, Sweden,1,92
1-ZD806,0,0,6/23/2014,0,0,0,8/20/2014,0,0,0,CNS,I,Closed,90,Covance,48,115,326, United States of America (the),1,58
1-ZD80F,0,0,7/27/2016,0,0,0,9/9/2016,0,0,0,CNS,II,Closed,160,Quintiles,72,103,329, United States of America (the),1,44
1-ZD80O,0,0,4/29/2016,0,0,0,6/9/2016,0,0,0,CNS,I,Closed,74,PPD,99,668,49," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,41
1-ZD857,0,0,1/19/2014,0,0,0,12/10/2014,0,0,0,GI,I,Closed,240,Quintiles,440,208,725, United States of America (the),1,325
1-ZD85G,0,0,3/19/2021,0,0,0,5/14/2021,0,0,0,GI,I,Cancelled,24,Quintiles,532,2073,244," Israel, Italy, Mexico, Poland, United States of America (the)",1,56
1-ZD863,0,0,4/14/2021,0,0,0,6/10/2021,0,0,0,GI,II,Planned,70,Quintiles,682,2010,NULL," Belgium, Brazil, Bulgaria, Colombia, France, Germany, Hungary, Israel, Italy, Korea (the Republic of), Lithuania, Mexico, Poland, Portugal, Ukraine, United States of America (the)",1,57
1-ZD87D,0,0,11/10/2014,0,0,0,12/18/2014,0,0,0,GI,II,Closed,63,Quintiles,248,160,594," Belgium, Brazil, Bulgaria, France, Hungary, Italy, Mexico, Poland, Portugal, United States of America (the)",1,38
1-ZD87X,0,1,8/18/2017,0,0,0,10/9/2017,0,0,0,GI,I,Closed,36,Quintiles,0,1728,98, China,1,52
1-ZD88A,1,0,7/27/2017,0,0,0,9/1/2017,0,0,0,GI,III,Closed,480,Quintiles,NULL,957,806," China, Korea (the Republic of), Malaysia, Taiwan (Province of China)",1,36
1-ZD88J,5,6,12/31/2018,0,0,0,11/22/2019,0,0,0,GI,III,Closed,693,IQVIA,7,952,1188," China, Korea (the Republic of), Malaysia, Taiwan (Province of China)",1,326
1-ZD8AP,0,2,10/27/2017,0,0,0,12/28/2017,0,0,0,CVM,III,Closed,600,Quintiles,71,1607,710, China,1,62
1-ZD8BA,0,0,3/19/2017,0,0,0,5/3/2017,0,0,0,CVM,I,Closed,64,Quintiles,40,1668,460, China,1,45
1-ZD8CA,0,0,9/23/2017,0,0,0,10/20/2017,0,0,0,CNS,I,Closed,72,PPD,54,82,703, United Kingdom of Great Britain and Northern Ireland (the),1,27
1-ZF5WP,0,0,7/16/2015,0,0,0,9/10/2015,0,0,0,CNS,I,Closed,48,PPD,38,98,344, United States of America (the),1,56
1-ZF5X1,0,0,4/19/2016,0,0,0,6/17/2016,0,0,0,CNS,I,Closed,40,PPD,99,82,175, United States of America (the),1,59
1-ZF5XK,0,0,1/6/2016,0,0,0,3/4/2016,0,0,0,CNS,I,Closed,11,PPD,NULL,62,128, United States of America (the),1,58
1-ZF5YO,0,0,9/3/2013,0,0,0,12/9/2013,0,0,0,CNS,II,Closed,300,Covance,103,218,518, United States of America (the),1,97
1-ZF5Z0,0,0,8/4/2014,0,0,0,10/14/2014,0,0,0,CNS,II,Closed,120,Covance,112,144,859, United States of America (the),1,71
1-ZF5ZJ,0,0,5/15/2017,0,0,0,8/8/2017,0,0,0,CNS,IIIB,Closed,7500,PPD,137,249,2278," Canada, Mexico, United States of America (the)",1,85
1-ZF60M,9,10,2/5/2019,0,0,0,4/4/2019,0,0,0,GI,IV,Closed,12,PPD,225,987,364, United States of America (the),1,58
1-ZF60Y,8,6,10/23/2019,0,0,0,12/18/2019,0,0,0,GI,IV,Preparation,60,IQVIA,226,1094,488, United States of America (the),1,56
1-ZOEF2,0,0,5/4/2017,0,0,0,7/25/2017,0,0,0,CNS,I,Closed,128,Quintiles,45,108,742, United States of America (the),1,82
1-ZOEFB,0,0,8/19/2016,0,0,0,11/7/2016,0,0,0,CNS,I,Closed,25,Quintiles,205,166,62,NULL,1,80
1-ZYOC0,0,0,2/6/2017,0,0,0,2/13/2017,0,0,0,CNS,0,Cancelled,150,In-House,173,2,3, United States of America (the),1,7
201501,0,0,10/9/2020,0,0,0,10/9/2020,1,0,0,RGH,I/II,Execution,10,IQVIA,0,0,262," Austria, Canada, France, Germany, Hungary, Italy, Japan, Poland, Spain, Sweden, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,0
241302,2,6,6/7/2019,0,0,0,4/26/2021,0,0,0,RGH,IV,Completed,40,IQVIA,496,294,1024, United States of America (the),1,689
241501,0,0,5/31/2021,0,0,0,7/2/2021,0,0,0,RGH,IV,Execution,50,IQVIA,418,268,1589," Austria, Denmark, France, Germany, Ireland, Italy, Netherlands (the), Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,32
241502,0,1,4/19/2021,0,0,0,6/1/2021,0,0,0,RGH,III,Cancelled,12,IQVIA,NULL,588,1512," Bulgaria, Canada, Germany, Hungary, Italy, Netherlands (the), Norway, Poland, Russian Federation (the), Serbia, South Africa, Spain, Sweden, Taiwan (Province of China), Thailand, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,43
251501,1,1,4/5/2019,0,0,0,4/30/2019,0,0,0,NULL,Phase 4,Completed - CSR Available,50,NULL,NULL,296,802, Korea (the Republic of),1,25
251602,1,1,4/21/2021,0,0,0,5/21/2021,0,0,0,NULL,Phase 4,Enrolment Completed,25,IQVIA India,NULL,948,789, India,1,30
471101,4,3,8/31/2020,0,0,0,11/9/2020,0,0,0,Plasma Derived Therapy,IV,Completed,36,IQVIA,90,93,1408," Australia, Canada, New Zealand, United States of America (the)",1,70
CS03,0,0,10/2/2017,0,0,0,11/30/2017,0,0,0,NULL,IV,Completed,50,Clinsupport,NULL,100,NULL," Austria, Germany",1,59
DX-2930-03,0,0,4/13/2017,0,0,0,5/10/2017,0,0,0,RGH,III,Completed,120,IQVIA,40,171,187," Canada, Germany, Italy, Jordan, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,27
DX-2930-04,2,2,11/4/2019,0,0,0,12/17/2019,0,0,0,RGH,III,Completed,250,"Red Maple Trials, Rho, Triumpharma",141,154,308," Canada, Germany, Italy, Jordan, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,43
HGT-HIT-094,1,1,9/28/2017,0,0,0,12/4/2017,0,0,0,RGH,III,Completed,48,PPD,205,364,911," Argentina, Australia, Canada, Colombia, France, Germany, Mexico, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,67
HGT-MLD-070,0,0,2/20/2017,0,0,0,3/13/2017,0,0,0,RGH,II,Completed,24,ICON / MAPI / Paradigm,214,555,1345," Argentina, Australia, Brazil, Denmark, France, Germany, Japan, Mexico, Poland",1,21
PAR-C10-008,0,0,1/30/2018,0,0,0,7/3/2018,0,0,0,RGH,III,Completed,40,Medpace,38,97,299, United States of America (the),1,154
ROPP-2008-01,0,0,4/27/2016,0,0,0,6/8/2016,0,0,0,RGH,II,Completed,120,PPD,80,211,280," Canada, Italy, Netherlands (the), Poland, Sweden, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,42
SHP465-112,0,0,10/5/2018,0,0,0,11/16/2018,0,0,0,CNS,I,Completed,24,PPD,NULL,173,178, United States of America (the),1,42
SHP465-308,0,0,1/18/2019,0,0,0,2/15/2019,0,0,0,CNS,III,Closed,80,PPD,NULL,133,107, United States of America (the),1,28
SHP465-309,0,0,6/8/2018,0,0,0,8/21/2018,0,0,0,CNS,III,Completed,60,PPD,NULL,110,127, United States of America (the),1,74
SHP615-301,1,1,10/15/2019,0,0,0,11/19/2019,0,0,0,CNS,III,Completed,25,IQVIA,151,308,687, Japan,1,35
SHP615-302,6,6,2/8/2021,1,1,0,3/22/2021,1,1,0,CNS,III,Completed,6,IQVIA,189,441,983, Japan,1,42
SHP616-300,0,0,7/24/2017,0,0,0,8/23/2017,0,0,0,Plasma Derived Therapy,III,Completed,66,PPD,262,225,332," Canada, Germany, Hungary, Israel, Romania, Spain, United States of America (the)",1,30
SHP616-301,0,0,5/4/2017,0,0,0,6/1/2017,0,0,0,Plasma Derived Therapy,III,Completed,12,Chiltern,NULL,314,756," Germany, Israel, Mexico, Romania, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,28
SHP620-303,2,3,9/29/2020,0,0,0,11/13/2020,0,0,0,RGH,III,Closed,351,PPD,135,245,1188," Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, France, Germany, Italy, Korea (the Republic of), Netherlands (the), Poland, Singapore, Spain, Sweden, Switzerland, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,45
SHP621-101,0,0,11/26/2017,0,0,0,1/22/2018,0,0,0,GI,I,Completed,22,NULL,70,170,0,NULL,1,57
SHP621-102,0,0,12/29/2017,0,0,0,3/8/2018,0,0,0,GI,I,Completed,16,NULL,44,58,0, United States of America (the),1,69
SHP621-301,0,0,2/15/2019,0,0,0,3/15/2019,0,0,0,GI,III,Completed,300,PPD,35,98,1036," Canada, United States of America (the)",1,28
SHP621-302,2,3,11/29/2019,0,0,0,12/27/2019,0,0,0,GI,III,Completed,200,PPD,21,148,1022," Canada, United States of America (the)",1,28
SHP621-303,0,0,4/30/2021,0,0,0,6/11/2021,0,0,0,GI,III,Execution,100,PPD,46,321,777, United States of America (the),1,42
SHP633-301,4,3,9/30/2020,0,0,0,10/14/2020,0,0,0,GI,III,Completed,10,IQVIA,859,343,546," Finland, France, Italy, United Kingdom of Great Britain and Northern Ireland (the)",1,14
SHP633-302,3,2,1/21/2020,0,0,0,6/8/2020,0,0,0,GI,III,Completed,10,IQVIA,255,411,882, Japan,1,139
SHP633-303,5,4,7/14/2020,0,0,0,10/9/2020,0,0,0,GI,III,Completed,39,IQVIA,155,212,242," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,87
SHP633-304,8,9,11/30/2020,0,0,0,1/25/2021,0,0,0,GI,III,Completed,57,TBD,122,276,1344," Belgium, Canada, Finland, France, Germany, Italy, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,56
SHP633-305,1,0,5/28/2021,0,0,0,6/11/2021,0,0,0,GI,III,Execution,9,IQVIA,87,362,881, Japan,1,14
SHP633-306,1,2,8/16/2019,0,0,0,10/4/2019,0,0,0,GI,III,Completed,5,IQVIA,124,279,120, Japan,1,49
SHP634-101,0,5,3/8/2019,0,0,0,2/17/2020,0,0,0,RGH,I,Completed,34,PPD,36,473,719," Canada, Denmark, Hungary, Korea (the Republic of), United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,346
SHP634-102,0,0,6/26/2017,0,0,0,8/22/2017,0,0,0,RGH,I,Completed,24,Parexel,225,98,6, United States of America (the),1,57
SHP634-103,0,0,11/3/2017,0,0,0,3/9/2018,0,0,0,RGH,I,Completed,58,"Clinical Pharmacology of Miami, INC",22,75,13, United States of America (the),1,126
SHP634-104,2,2,2/25/2021,0,0,0,3/26/2021,0,0,0,RGH,I,Closed,14,PPD,200,768,NULL," Finland, France, Israel, Lithuania, Portugal, Slovenia, Spain, United Kingdom of Great Britain and Northern Ireland (the)",1,29
SHP634-301,2,2,4/30/2021,0,0,0,7/9/2021,0,0,0,RGH,III,Closed,12,IQVIA,189,1052,NULL, Japan,1,70
SHP634-401,2,1,1/18/2021,0,0,0,3/17/2021,0,0,0,RGH,IV,Execution,92,PPD,108,545,1194," Belgium, Canada, Denmark, France, Germany, Italy, Korea (the Republic of), Netherlands (the), Norway, Portugal, Spain, Sweden, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,58
SHP634-404,2,7,4/14/2020,0,0,0,12/17/2020,0,0,0,GI,IV,Closed,32,TBD,86,399,146," Canada, Denmark, Hungary, United States of America (the)",1,247
SHP639-101,0,0,5/30/2018,0,0,0,11/13/2018,0,0,0,Ophthalmology,I,Completed,84,PPD,118,155,287," Belgium, United States of America (the)",1,167
SHP640-301,0,0,6/4/2020,0,0,0,7/8/2020,0,0,0,Ophthalmology,III,Completed,540,IQVIA,30,271,1149," Australia, Austria, Canada, Colombia, Estonia, France, Germany, Hungary, India, Israel, Italy, Peru, Philippines (the), Poland, South Africa, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,34
SHP640-302,0,0,12/31/2019,0,0,0,2/14/2020,0,0,0,Ophthalmology,III,Completed,284,IQVIA,30,275,990," India, Philippines (the), Puerto Rico, United States of America (the)",1,45
SHP640-303,0,0,10/3/2018,0,0,0,11/15/2018,0,0,0,Ophthalmology,III,Completed,721,IQVIA,32,210,261," Australia, Austria, Canada, Colombia, Estonia, France, Germany, Hungary, India, Israel, Italy, Peru, Philippines (the), Poland, Puerto Rico, South Africa, Spain, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,43
SHP643-101,0,0,5/30/2018,0,0,0,7/30/2018,0,0,0,RGH,I,Completed,32,PPD,NULL,64,7, United States of America (the),1,61
SHP643-102,3,3,11/18/2019,0,0,0,1/9/2020,0,0,0,RGH,I,Completed,190,PPD,NULL,99,77, United States of America (the),1,52
SHP647-301,0,1,7/22/2020,0,0,0,12/4/2020,0,0,0,GI,III,Completed,825,PPD,NULL,206,803," Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Kenya, Korea (the Republic of), Latvia, Lebanon, Lithuania, Malaysia, Mexico, Moldova (the Republic of), Netherlands (the), New Zealand, Norway, Poland, Portugal, Romania, Russian Federation (the), Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the), Viet Nam",1,135
SHP647-302,0,0,7/15/2020,0,0,0,11/9/2020,0,0,0,GI,III,Completed,825,PPD,NULL,144,868," Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Jordan, Kenya, Korea (the Republic of), Latvia, Lebanon, Lithuania, Malaysia, Mexico, Netherlands (the), New Zealand, Norway, Poland, Portugal, Romania, Russian Federation (the), Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the), Viet Nam",1,117
SHP647-305,0,1,7/7/2020,0,0,0,11/30/2020,0,0,0,GI,III,Completed,1032,PPD,NULL,251,574," Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Kenya, Korea (the Republic of), Latvia, Lebanon, Lithuania, Malaysia, Mexico, Netherlands (the), New Zealand, Norway, Poland, Portugal, Romania, Russian Federation (the), Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the), Viet Nam",1,146
SHP647-306,0,1,8/18/2020,0,0,0,11/25/2020,0,0,0,GI,III,Completed,1032,PPD,NULL,208,639," Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Jordan, Kenya, Korea (the Republic of), Latvia, Lebanon, Lithuania, Malaysia, Mexico, Netherlands (the), New Zealand, Norway, Poland, Portugal, Romania, Russian Federation (the), Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the), Viet Nam",1,99
SHP655-101,2,2,6/10/2020,1,0,0,8/5/2020,0,0,0,RGH,I/II,Execution,56,IQVIA,361,103,168, United States of America (the),1,56
SHP671-101,3,2,2/24/2021,0,0,0,3/17/2021,0,0,0,NULL,I,Study Withdrawn,10,NULL,NULL,107,94,NULL,1,21
SHP682-101,6,6,12/18/2020,0,0,0,2/26/2021,0,0,0,NULL,I,Closed,48,TBD,333,7,122,NULL,1,70
SHP684-101,1,1,12/15/2020,0,0,0,1/19/2021,0,0,0,RGH,I,Closed,166,TBD,207,337,136,NULL,1,35
SHPELA-701,2,2,11/30/2020,0,0,0,12/9/2020,0,0,0,RGH,IV,Completed,25,IQVIA,NULL,905,203, Mexico,1,9
SHP-GCB-402,1,1,2/1/2021,0,0,0,4/30/2021,0,0,0,RGH,IV,Completed,19,PPD,1353,341,300," Australia, Austria, Canada, Germany, Israel, Italy, Portugal, Spain, Turkey, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,88
SHP-GCB-702,0,0,3/31/2020,0,0,0,6/30/2020,0,0,0,NULL,Phase 4,"Active, Recruiting",150,NULL,NULL,130,NULL, Germany,1,91
SHPGCB-703,1,1,12/16/2019,0,0,0,1/15/2020,0,0,0,NULL,Phase 4,"Active, Recruiting",45,NULL,NULL,168,NULL, France,1,30
SPD489-348,0,1,1/3/2020,0,0,0,1/30/2020,0,0,0,CNS,III,Completed,100,PPD,57,304,1225," Canada, United States of America (the)",1,27
TAK-073-1501,0,0,1/30/2020,0,0,0,1/30/2020,0,0,0,RGH,I/II,Cancelled,8,PPD,62,105,NULL, United States of America (the),1,0
TAK-620-1019,0,0,11/25/2019,0,0,0,3/3/2020,0,0,0,RGH,I,Study Terminated,38,PPD,29,114,NULL, United States of America (the),1,99
TAK-743-1002,3,3,3/3/2021,0,0,0,4/7/2021,0,0,0,RGH,I,Study Terminated,24,IQVIA,NULL,143,111, United States of America (the),1,35
TAK-743-1003,2,1,12/16/2020,0,0,0,2/1/2021,0,0,0,Plasma Derived Therapy,I,Completed,12,Celerion,NULL,14,14, United States of America (the),1,47
TAK-888-2001,6,7,3/10/2021,0,0,0,3/28/2021,0,0,0,Plasma Derived Therapy,III,Study Withdrawn,500,NULL,89,87,125,NULL,1,18
TED-C13-003,0,0,1/9/2015,0,0,0,2/5/2015,0,0,0,GI,III,Completed,42,Psi,49,165,274," United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,27
TED-C14-006,0,0,7/28/2017,0,0,0,10/20/2017,0,0,0,GI,III,Completed,34,IQVIA,129,469,190," Belgium, Canada, Finland, France, Germany, Italy, United Kingdom of Great Britain and Northern Ireland (the), United States of America (the)",1,84
VV_DEN_109,0,0,6/26/2020,0,0,0,8/21/2020,0,0,0,NULL,Phase IIa,Cancelled,90,PPD,63,504,NULL, United States of America (the),1,56
VV_DEN_203-2,0,0,4/1/2016,0,0,0,12/30/2016,0,0,0,NULL,Phase IIa,Closed,360,Chiltern,71,138,446," Colombia, Puerto Rico, Singapore, Thailand",1,273
VV_DEN_204,1,2,2/18/2019,0,0,0,8/1/2019,0,0,0,NULL,Phase 2,Completed,1800,IQVIA,0,267,70," Colombia, Dominican Republic (the), Panama, Philippines (the), Thailand",1,164
VV_DEN_205,0,0,9/18/2017,0,0,0,1/11/2018,0,0,0,NULL,Phase IIa,Closed,400,PPD,130,134,448, Singapore,1,115
VV_DEN_301,0,1,1/7/2019,1,1,0,4/2/2019,1,1,0,NULL,Phase IIIa,Execution,20100,PPD,79,630,205," Brazil, Colombia, Dominican Republic (the), Nicaragua, Panama, Philippines (the), Sri Lanka, Thailand",1,85
VV_DEN_302,0,0,1/3/2020,0,0,0,1/10/2020,0,0,0,NULL,Phase II,Planned,450,PPD,157,411,NULL,NULL,1,7
VV_DEN_304,0,0,1/14/2019,0,0,0,5/22/2019,0,0,0,NULL,Phase III,Closed,924,PPD,517,209,24, United States of America (the),1,128
VV_DEN_305,0,3,5/13/2019,0,0,0,11/4/2019,0,0,0,NULL,Phase III,Closed,900,PPD,306,436,27, United States of America (the),1,175
VV_DEN_307,2,7,3/20/2020,0,0,0,12/15/2020,0,0,0,NULL,Phase IIIa,Completed,200,IQVIA,126,280,168, United States of America (the),1,270
VV_DEN_309,0,0,1/3/2020,0,0,0,1/10/2020,0,0,0,NULL,Phase IIIa,Cancelled,250,PPD,63,NULL,63,NULL,1,7
VV_DEN_310,0,0,1/3/2020,0,0,0,1/10/2020,0,0,0,NULL,Phase IIIa,Planned,900,PPD,63,NULL,63,NULL,1,7
VV_DEN_312,0,0,3/1/2021,0,0,0,7/9/2021,0,0,0,NULL,Phase IIIa,Hold,475,PPD,99,NULL,84, United States of America (the),1,130
VV_DEN_313,3,7,10/28/2020,0,0,0,5/7/2021,0,0,0,NULL,Phase II,Execution,200,PPD,0,276,60," Panama, Philippines (the)",1,191
VV_DEN_314,1,2,7/9/2019,0,0,0,10/2/2019,0,0,0,NULL,Phase IIIa,Closed,900,PPD,196,623,106, United Kingdom of Great Britain and Northern Ireland (the),1,85
VV_DEN_315,1,0,1/28/2019,0,0,0,5/8/2019,0,0,0,NULL,Phase III,Closed,400,PPD,249,412,115, Mexico,1,100
VV_NOR_202,0,0,6/20/2018,0,0,0,8/30/2018,0,0,0,NULL,Phase IIa,Completed,840,IQVIA,97,470,763," Colombia, Finland, Panama",1,71
VV_NOR_204,0,0,9/29/2017,0,0,0,2/5/2018,0,0,0,NULL,Phase IIa,Completed,325,PPD,33,552,214, United States of America (the),1,129
VV_NOR_211,0,0,6/16/2018,0,0,0,8/8/2018,0,0,0,NULL,Phase IIb,Completed,4176,IQVIA,33,323,686, United States of America (the),1,53
VV_ZIK_101,4,4,11/24/2020,1,0,0,6/14/2021,1,0,0,NULL,Phase I,Execution,240,PRA Health Sciences,41,302,333," Puerto Rico, United States of America (the)",1,202
VV_ZIK_201,2,2,5/9/2021,1,0,0,7/4/2021,1,0,0,NULL,Phase II,Planned,648,NULL,1175,NULL,133, United States of America (the),1,56
